Hatri Pharma Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 8.83 Cr
as on 09-12-2024
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 13.50 Cr
as on 09-12-2024
- Revenue %
(FY 2022)
- Profit 1.23%
(FY 2022)
- Ebitda
- Net Worth 106.02%
(FY 2022)
- Total Assets 77.41%
(FY 2022)
About Hatri Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 8.83 Cr.
The company currently has active open charges totaling ₹13.50 Cr.
Mohan Enaganuri, Rebala Rupakala, Ravindra Paidimarla, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24232AP2010PTC116314
- Company No.
069596
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 2010
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Nellore, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hatri Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohan Enaganuri  | Director | 21-Jul-2010 | Current |
| Rebala Rupakala | Director | 30-Oct-2017 | Current |
| Ravindra Paidimarla | Director | 12-May-2022 | Current |
| Archana Guddeti | Director | 26-Jul-2023 | Current |
| Dayakar Vangala | Director | 16-Mar-2023 | Current |
| Sumalatha Ambarapu | Director | 09-Aug-2023 | Current |
Financial Performance of Hatri Pharma.
Hatri Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 1.23% increase in profit. The company's net worth Soared by an impressive increase of 106.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Hatri Pharma?
In 2022, Hatri Pharma had a promoter holding of 76.92% and a public holding of 23.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Reddys Therapeutics Private LimitedActive 8 years 2 monthsMohan Enaganuri and Rebala Rupakala are mutual person
- Emr Laboratories Private LimitedActive 8 years 2 months
Mohan Enaganuri and Rebala Rupakala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Sep 2020 | ₹13.50 Cr | Open |
How Many Employees Work at Hatri Pharma?
Unlock and access historical data on people associated with Hatri Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hatri Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hatri Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
